Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling human beings to improve their health span through targeting the causes of age-related diseases and ageing itself.

CDP is an innovative platform and can be applied to many different indications that involve excess cholesterol in their pathology. These include multi-billion dollar markets with high unmet need, such as atherosclerosis, as well as orphan conditions such as homozygous familial hypercholesterolemia.

Repair Biotechnologies has at present strong preclinical evidence in cells and animal models for the efficacy of CDP therapy. We have a clear path ahead to become a platform company with multiple approved therapies.